Zealand Pharma A/S (CPH:ZEAL)
Denmark · Delayed Price · Currency is DKK | Market Cap | 22.92B -20.5% |
| Revenue (ttm) | 9.24B +16,519.7% |
| Net Income | 6.40B |
| EPS | 89.42 |
| Shares Out | 70.24M |
| PE Ratio | 3.65 |
| Forward PE | 19.08 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,069,347 |
| Open | 299.80 |
| Previous Close | 326.30 |
| Day's Range | 237.50 - 299.80 |
| 52-Week Range | 233.50 - 556.00 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | 525.73 (+111.39%) |
| Earnings Date | Aug 13, 2026 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for ZEAL stock is "Buy." The 12-month stock price target is kr 525.73, which is an increase of 111.39% from the latest price.
News
Zealand Pharma (ZLDPF) Shares Plunge 26% Amid Side Effect Concerns
Zealand Pharma (ZLDPF) Shares Plunge 26% Amid Side Effect Concerns
Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot's Side Effects
Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said.
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
The drugmaker’s shares tumbled in Copenhagen after saying a fifth of users discontinued its weight-loss drug because of gastrointestinal issues.
Zealand Pharma shares drop 20% as obesity drug side effects raise concerns
Zealand Pharma's shares fell more than 20% in early trade on Monday after trial data showed its obesity drug survodutide had worse side effects and higher patient dropout rates than riv...
Zealand Pharma announces Boehringer’s phase III results of survodutide
Zealand Pharma (ZLDPF) announced that Boehringer Ingelheim has reported positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide, Synchronize-1 and Synchronize-...
Zealand Pharma (ZLDPF) Reports Promising Weight Loss Results from Petrelintide Study
Zealand Pharma (ZLDPF) Reports Promising Weight Loss Results from Petrelintide Study
Zealand Pharma presents additional data from ZUPREME-1 trial
Zealand Pharma (ZLDPF) announced the presentation of additional data from its Phase 2 ZUPREME-1 trial, evaluating investigational petrelintide, at the 2026 Scientific Sessions of the American Diabetes...
Zealand Pharma price target raised to DKK 300 from DKK 275 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Zealand Pharma (ZLDPF) to DKK 300 from DKK 275 and keeps a Hold rating on the shares.
Zealand Pharma Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted progress on the Metabolic Frontier 2030 strategy, with major clinical data for petrelintide and survodutide expected at ADA. Strong financial positioning, new research partnerships, and a focus on patient adherence and market expansion were emphasized.
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
Press release – No. 11 / 2026 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, May 27, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a bi...
Zealand Pharma To Present ZUPREME-1 Results Of Petrelintide At ADA 2026
(RTTNews) - Zealand Pharma A/S (ZEAL.CO), a biotechnology company focused on advancing medicines for obesity and metabolic health, on Wednesday reported it will present its data from the obesity and m...
Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions
Press release – No. 10 / 2026 Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePos...
Zealand Pharma Earnings Call Transcript: Q1 2026
Q1 2026 saw major clinical and financial milestones, including strong phase II and III results for obesity candidates, robust cash reserves, and the launch of a $200 million share buyback. Strategic partnerships and a focus on R&D underpin a positive outlook for 2026.
Zealand Pharma Quarterly report: Q1 2026
Zealand Pharma has published its Q1 2026 quarterly earnings report on May 7, 2026.
Zealand Pharma Slides: Q1 2026
Zealand Pharma has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance
Danish drug developer Zealand Pharma reported a smaller-than-expected first-quarter operating loss on Thursday, boosted by strong momentum in its obesity drug pipeline, and said it would l...
Zealand Pharma upgraded to Buy from Hold at SEB Equities
SEB Equities analyst Thomas Bowers upgraded Zealand Pharma (ZLDPF) to Buy from Hold with a DKK 475 price target
Zealand Pharma, Roche to advance petrelintide for weight management to Phase 3
Zealand Pharma A/S (ZLDPF) announced formal endorsement to advance petrelintide, an amylin analog for chronic weight management, into Phase 3 trials with its partner Roche (RHHBY). The initiation is p...
Zealand Pharma appoints Eric Rojas as VP, head of IR
Zealand Pharma (ZLDPF) announced the appointment of Eric Rojas, Vice President, Investor Relations, effective April 15, 2026. Eric will report to Henriette Wennicke, CFO, and will be based in Massachu...
Zealand Pharma establishes U.S. research hub in Cambridge, Massachusetts
Zealand Pharma (ZLDPF) announced the establishment of a new research hub in Cambridge, Massachusetts, in the greater Boston area. The facility will serve as Zealand Pharma’s primary U.S. address and…
Zealand Pharma Slides: Corporate presentation
Zealand Pharma has posted slides in relation to its latest quarterly earnings report, which was published on March 17, 2026.
Zealand Pharma price target lowered to DKK 275 from DKK 450 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 275 from DKK 450 and keeps a Hold rating on the shares.
Zealand Pharma Transcript: Barclays 28th Annual Global Healthcare Conference
The discussion highlighted a robust pipeline targeting obesity and metabolic diseases, with Petrelintide showing strong efficacy and tolerability, and Survodutide poised for major phase III data this year. Strategic partnerships, financial strength, and upcoming clinical milestones position the company for significant growth.
Zealand Pharma Slides: Barclays 28th Annual Global Healthcare Conference
Zealand Pharma has posted slides in relation to its latest quarterly earnings report, which was published on March 11, 2026.
Zealand Pharma price target lowered to DKK 460 from DKK 1,000 at JPMorgan
JPMorgan lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 460 from DKK 1,000 and keeps an Overweight rating on the shares.